| Literature DB >> 28389245 |
Yi Li1, Jia-Ming Wen2, Chuan-Jun Du2, Su-Min Hu2, Jia-Xi Chen2, Shi-Geng Zhang2, Nan Zhang2, Feng Gao2, Shao-Jiang Li2, Xia-Wa Mao2, Hiroshi Miyamoto3, Ke-Feng Ding4.
Abstract
Thymol is a phenolic compound with various pharmacological activities such as anti-inflammatory, anti-bacterial and anti-tumor effects. However, the effect of thymol on bladder cancer cell growth is still elusive. The purpose of this study is to investigate the efficacy of thymol in bladder cancer cells and its underlying mechanism. Thymol inhibited bladder cancer cell proliferation in a dose and time-dependent manner. We also observed cell cycle arrest at the G2/M phase after the treatment of thymol. Moreover, thymol could induce apoptosis in bladder cancer cells via the intrinsic pathway along with caspase-3/9 activation, release of cytochrome c and down-regulation of anti-apoptotic Bcl-2 family proteins. The activation of JNK and p38 was also critical for thymol-induced apoptosis since it was abrogated by the treatment of JNK inhibitor (SP600125), and p38 inhibitor (SB203580) but not ERK inhibitor (SCH772984). Furthermore, the generation of ROS (reactive oxygen species) was detected after the treatment of thymol. ROS scavenger NAC (N-acetyl cysteine) could block the thymol-triggered apoptosis and activation of MAPKs. These findings offer a novel therapeutic approach for bladder cancer.Entities:
Keywords: Apoptosis; Bladder cancer; MAPKs; ROS; Thymol
Mesh:
Substances:
Year: 2017 PMID: 28389245 DOI: 10.1016/j.bbrc.2017.04.009
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN: 0006-291X Impact factor: 3.575